Inovio Pharmaceuticals (INO) Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Inovio Pharmaceuticals (INOResearch Report) yesterday and set a price target of $20.00. The company’s shares closed last Tuesday at $10.73.

According to, McCarthy is a 5-star analyst with an average return of 29.3% and a 44.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and Interpace Diagnostics Group.

Inovio Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $13.57.

See today’s analyst top recommended stocks >>

The company has a one-year high of $33.79 and a one-year low of $2.19. Currently, Inovio Pharmaceuticals has an average volume of 16.55M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.